Biodesix Inc (BDSX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biodesix Inc (BDSX) has a cash flow conversion efficiency ratio of -0.171x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.56 Million) by net assets ($9.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Biodesix Inc for the company's overall valuation and market capitalisation.
Biodesix Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Biodesix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Biodesix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biodesix Inc ranked by their cash flow conversion efficiency. See how well can Biodesix Inc service its debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Oak Valley Bancorp
NASDAQ:OVLY
|
0.038x |
|
Legato Merger Corp. III
NYSE MKT:LEGT
|
-0.001x |
|
Patel Engineering Limited
NSE:PATELENG
|
0.086x |
|
Ananti Inc
KQ:025980
|
0.009x |
|
Hua Jung Components Co Ltd
TWO:5328
|
0.214x |
|
Weifu High Tech Group
SHE:200581
|
0.049x |
|
Tehmag Foods
TWO:1264
|
0.009x |
|
Isabella Bank Corporation
NASDAQ:ISBA
|
0.031x |
Annual Cash Flow Conversion Efficiency for Biodesix Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Biodesix Inc from 2018 to 2025. View Biodesix Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-2.46 Million | $-23.27 Million | 9.441x | +505.11% |
| 2024-12-31 | $20.88 Million | $-48.65 Million | -2.330x | +53.33% |
| 2023-12-31 | $4.58 Million | $-22.87 Million | -4.993x | -128.80% |
| 2022-12-31 | $20.61 Million | $-44.97 Million | -2.182x | -52.55% |
| 2021-12-31 | $19.73 Million | $-28.22 Million | -1.431x | -175.65% |
| 2020-12-31 | $41.17 Million | $-21.37 Million | -0.519x | -645.97% |
| 2019-12-31 | $-228.54 Million | $-21.73 Million | 0.095x | +6.50% |
| 2018-12-31 | $-198.03 Million | $-17.68 Million | 0.089x | -- |
About Biodesix Inc
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also pro… Read more